Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new era for NeuBase
August 2019
SHARING OPTIONS:

PITTSBURGH—NeuBase Therapeutics Inc. and Ohr Pharmaceutical Inc. completed their merger last month, along with related financings. Following the closing of the merger, the company entered into a definitive purchase agreement with Greenlight Capital for the sale of NeuBase common stock. Upon the closing of the private placement, which was slated for July 15, Greenlight Capital will hold approximately 9 percent of NeuBase common stock. The combined company will be known as NeuBase Therapeutics Inc.
 
“This is an important milestone for NeuBase as we enter the public market with the goal of creating a dynamic, high-impact company in one of the most promising sectors of the life sciences,” said Dr. Dietrich A. Stephan, chairman and CEO of NeuBase. “Given our PATrOL platform’s potential to safely and efficiently modify the function of the human genome and transcriptome, we envision building a company with the potential to help transform the health of the global population.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.